Clinical Trials Sponsored by Bionorica SE

Total 254 results

Bionorica SE

Active, not recruiting

Skin Efficacy and Tolerability of a Cosmetic Product Combination Over 3 Months in Subjects With Atopic Eczema (AtoCare-OS)

Atopic Dermatitis | Eczema-Prone Skin

Germany
Bionorica SE

Completed

BX-1 in Spasticity Due to Multiple Sclerosis

Spasticity Due to Multiple Sclerosis

Hungary, Czechia, Germany, Poland, Spain
Bionorica SE

Completed

Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI)

Urinary Tract Infection

Ukraine
Bionorica SE

Completed

Trial With Bronchipret and Sinupret to Evaluate Acceleration of Mucociliary Clearance (MCC)

Current Smokers

Belgium
Bionorica SE

Completed

Assessment of Skin Tolerance and Efficacy of a Cosmetic Product After 4 Weeks of Use on Subjects With Atopic Dermatitis

Eczema-Prone Skin | Atopic Diathesis

Germany
Bionorica SE

Completed

Sinupret Extract Coated Tablets in Chronic Rhinosinusitis

Chronic Rhinosinusitis

Germany, Poland
Bionorica SE

Completed

Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs

Urinary Tract Infection

Germany
Bionorica SE

Completed

Efficacy and Safety of Two Dosages of a Herbal Medicinal Product (Dry Extract BNO 1016) in Chronic Rhinosinusitis

Chronic Sinusitis

Belgium
Bionorica SE

Terminated

Efficacy and Safety of 20 mg (2 Tablets of 10mg)VAC BNO 1095 FCT on Cyclic Mastodynia and PMS

Mastodynia | Premenstrual Syndrome

Germany
Bionorica SE

Completed

Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis

Acute Rhinosinusitis

Germany
Bionorica SE

Completed

Dose-dependent Effects of VAC BNO 1095 on Cyclic Mastodynia and Premenstrual Syndrome

Premenstrual Syndrome | Cyclic Mastodynia

Czech Republic
Bionorica SE
FGK Clinical Research GmbH

Recruiting

Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea

Primary Dysmenorrhea

Poland, Hungary, Germany, Czechia, Austria, Sweden
Charite University, Berlin, Germany
Bionorica SE

Recruiting

Treating Nightmares in Posttraumatic Stress Disorder With Dronabinol

Posttraumatic Stress Disorder

Germany
Ivano-Frankivsk National Medical University
Bionorica SE

Completed

Study of Imupret Application in the Technology of Delayed Prescription of Antibiotics in Patients With Acute Tonsillitis

Acute Tonsillitis

Ukraine
West German Center of Diabetes and Health
Bionorica SE

Completed

Determination of Postprandial Glycemic Responses by Continuous Glucose Monitoring in a Real-World Setting

Postprandial Glucose Response | Glycaemic Index | Continous Glucose Measurement

Germany
Dr. Struk Tetiana
Bionorica SE

Unknown

Study of the Effects of Cyclodynon on Reducing the Cumulative Risk of Breast Cancer Development in a Female Aged 40-52 (BIO-CYCL)

Mammographic Breast Density

Ukraine
Arbeitsgemeinschaft medikamentoese Tumortherapie
Medical University of Graz; Bionorica SE; Unidata Geodesign

Active, not recruiting

Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer

Chemotherapy-induced Nausea and Vomiting | Pancreatic Cancer Metastatic | Pancreatic Cancer Non-resectable

Austria, Germany
Bionorica Research GmbH

Completed

Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis

Central Neuropathic Pain in Multiple Sclerosis

Germany
Dr. Frank Behrens
Bionorica SE

Recruiting

Effect of Bronchipret on Antiviral Immune Response in Patients With Mild COVID-19 (BroVID)

COVID-19

Germany
Dr. Frank Behrens
Bionorica SE

Active, not recruiting

Impact of Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo (SILVER)

Drug-induced Liver Injury

Germany
Biomerica

Completed

Specimen Collection Study Protocol

Focus in on Collecting Paired Specimens for Matrix Equivalency

United States
Biomerica

Completed

Endpoint Determination Study Protocol

Irritable Bowel Syndrome

United States
Biomerica

Completed

Specimen Collection Study for H. Pylori Testing

Helicobacter Infections

United States
Bionomics Limited

Completed

A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD) (ATTUNE)

Post-Traumatic Stress Disorder

United States, United Kingdom
Bionomics Limited

Completed

A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder (PREVAIL)

Social Anxiety Disorder

United States
Bionomics Limited

Completed

A Study of BNC210 in Elderly Patients With Agitation

Agitation in the Elderly

Australia
Bionomics Limited

Completed

Phase II Study of BNC210 in PTSD (RESTORE)

Post-Traumatic Stress Disorder

United States, Australia
BioNTech SE

Recruiting

A Clinical Trial in Healthy Volunteers to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

Genital Herpes Simplex Type 2

United States
BioNTech SE

Recruiting

Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors

Solid Tumor

United States, United Kingdom, Spain, Singapore
BioNTech SE

Recruiting

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer (LuCa-MERIT-1)

Non-Small Cell Lung Cancer

Spain, Germany, Turkey, United States, Hungary, United Kingdom, Poland
BioNTech SE

Recruiting

Dose Escalation Trial of BNT152+153 in Patients With Cancer

Solid Tumor

United States, Czechia
BioNTech SE

Terminated

PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) (PRO-MERIT)

Prostate Cancer

United States, Germany, United Kingdom, Hungary
BioNTech SE

Active, not recruiting

Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

Malaria

United States
BioNTech SE

Active, not recruiting

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

Solid Tumor | Extensive-stage Small Cell Lung Cancer

United States, Spain, United Kingdom, Germany
BioNTech SE

Completed

A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects

COVID-19 | SARS-CoV-2 Infection

Germany
BioNTech SE

Recruiting

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

Malaria

United States
BioNTech SE

Recruiting

Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers

Tuberculosis

South Africa
BioNTech SE

Recruiting

Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers

Tuberculosis

Germany
BioNTech SE

Recruiting

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)

Recurrent Head and Neck Cancer | Unresectable Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Cancer

Germany, United States, France, United Kingdom, Korea, Republic of, Spain, Poland, Belgium, Brazil, Taiwan, Italy, Canada, Czechia, Australia, Turkey, Mexico, Chile, Argentina, Austria, Hungary, Portugal, Sweden
BioNTech SE

Completed

A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults

Covid-19 | Protection Against COVID-19

Germany
BioNTech SE

Completed

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

COVID-19 | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | SARS (Disease)

United States, Germany, Turkey, South Africa
BioNTech SE

Terminated

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors

Gastric Cancer | Pancreatic Cancer | Solid Tumor | Metastatic Cancer | Cholangiocarcinoma | Esophageal Adenocarcinoma | Biliary Tract Cancer | Gastroesophageal Junction Adenocarcinoma

United States, Canada
BioNTech SE

Completed

Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma (Lipo-MERIT)

Melanoma

Germany
BioNTech SE

Active, not recruiting

A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults

RNA Virus Infections | Virus Diseases | Vaccine Adverse Reaction | Infection Viral | Infections, Respiratory | Protection Against COVID-19 and Infections With SARS CoV 2

Germany
BioNTech SE

Recruiting

Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma

Pancreatic Cancer

United States
BioNTech SE

Recruiting

A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines

Monkeypox

United Kingdom, United States
Decathlon SE

Recruiting

Assessment of the Safety and Performance of an Elbow Brace in the Prevention of Injuries During Sports Practice

Epicondylitis | Elbow Injury | Tendonitis Elbow

France
BioNTech SE

Recruiting

Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy

Colorectal Cancer Stage II | Colorectal Cancer Stage III

United States, Spain, Germany, Belgium
BioNTech SE

Active, not recruiting

BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors

Solid Tumor

United States, Spain
BioNTech SE
Pfizer

Recruiting

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

COVID-19 | Influenza

United States

3

Subscribe